Overview
The aim of this trial is to explore the real-world effectiveness and poteintial predictors of Sacituzumab Govitecan in Chinese metastatic breast cancer patients.
Eligibility
Inclusion Criteria:
- Patients aged over 18 years old.
- Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
- Plan to receive or has received Sacituzumab Govitecan monotherapy
- Available medical history.
Exclusion Criteria:
- Incomplete medical history.
- Pregnancy or breast-breeding